(Q34677773)

3 August 2017

1 reference

title

Intermediate- and high-risk melanoma (English)

1 reference

3 August 2017

Sanjiv S Agarwala

1

1 reference

3 August 2017

publication date

1 June 2002

1 reference

Current Treatment Options in Oncology

3 August 2017

published in

1 reference

3 August 2017

volume

3

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

205-217

1 reference

A new American Joint Committee on Cancer staging system for cutaneous melanoma

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-002-0010-7

Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-002-0010-7

Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-002-0010-7

Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-002-0010-7

Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-002-0010-7

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-002-0010-7

A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-002-0010-7

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-002-0010-7

Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-002-0010-7

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

12 December 2020

Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma

1 reference

12 December 2020

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

1 reference

12 December 2020

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases

1 reference

12 December 2020

Evolution of variable and constant domains and joining segments of rearranging immunoglobulins.

1 reference

12 December 2020

Sentinel lymph node micrometastasis from melanoma. Proven methodology and evolving significance

1 reference

12 December 2020

Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma

1 reference

12 December 2020

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

12 December 2020

Extent of lymph node dissection in melanoma of the trunk or lower extremity

1 reference

12 December 2020

Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck

1 reference

12 December 2020

Impact of clinical trials on the treatment of melanoma

1 reference

12 December 2020

Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system

1 reference

12 December 2020

Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial

1 reference

12 December 2020

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

12 December 2020

Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities

1 reference

12 December 2020

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

12 December 2020

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

12 December 2020

Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients

1 reference

12 December 2020

The orderly progression of melanoma nodal metastases

1 reference

12 December 2020

10.1007/S11864-002-0010-7

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1004526106

0 references

1 reference